ASCO News In Brief: IDEC Pharmaceuticals IDEC-C2B8
Executive Summary
IDEC Pharmaceuticals IDEC-C2B8: Overall response rate of 47.9% reported in preliminary results of Phase III pivotal trial of single-agent antibody treatment for patients with relapsed low-grade or follicular non-Hodgkin's lymphoma. Fifty of 166 evaluable patients have been analyzed and full results should be available in December 1996, the company said. The tumor marker gene, bcl-2, reverted from positive to negative in the peripheral blood of 12 of 16 patients and in the bone marrow of six of 12 patients evaluated. IDEC is developing IDEC-C2B8 in collaboration with Genentech, Roche and Zenyaku Kogyo of Japan...